NanoViricides Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:4em;'>NI</div>
NNVC -- USA Stock  

USD 3.82  0.01  0.26%

While some baby boomers are getting worried about healthcare space, it is reasonable to go over NanoViricides Inc NEW. We are going to cover the possibilities of making NanoViricides Inc into your portfolio. Is NanoViricides NEW current valuation justified? We will cover the entity valuation to give you a better outlook on taking a position in the stock.
Published over a month ago
View all stories for NanoViricides Inc | View All Stories
Is NanoViricides NEW outlook positive for September 2020?
This firm currently holds 1.18 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the firm is not taking enough advantage from borrowing. The company has a current ratio of 2.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. The company secures a Beta (Market Risk) of -1.5071, which conveys a somewhat significant risk relative to the market. Let's try to break down what NanoViricides's beta means in this case. As returns on the market increase, returns on owning NanoViricides Inc are expected to decrease by larger amounts. On the other hand, during market turmoil, NanoViricides Inc is expected to outperform it. Even though it is essential to pay attention to NanoViricides NEW price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. NanoViricides Inc exposes twenty-eight different technical indicators, which can help you to evaluate its performance. NanoViricides NEW has an expected return of -0.51%. Please be advised to verify NanoViricides Inc NEW downside variance, and the relationship between the treynor ratio and kurtosis to decide if NanoViricides NEW stock performance from the past will be repeated at some point in the near future.
We determine the current worth of NanoViricides Inc NEW using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NanoViricides NEW based exclusively on its fundamental and basic technical indicators. By analyzing NanoViricides Inc's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of NanoViricides Inc's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of NanoViricides Inc. We calculate exposure to NanoViricides Inc's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NanoViricides Inc's related companies.

NanoViricides NEW Investment Alerts

NanoViricides investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring NanoViricides Inc NEW performance across your portfolios.Please check all investment alerts for NanoViricides

NanoViricides Inc Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare NanoViricides value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NanoViricides Inc competition to find correlations between indicators driving the intrinsic value of NanoViricides.

How NanoViricides utilizes its cash?

To perform a cash flow analysis of NanoViricides Inc, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NanoViricides Inc is receiving and how much cash it distributes out in a given period. The NanoViricides Inc cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NanoViricides Inc Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (6.12 Million)

Sale by Theracour Pharma Inc of 10000 shares of NanoViricides Inc

Legal trades by NanoViricides Inc insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NanoViricides Inc NEW insider trading alert for sale of common stock by Theracour Pharma Inc, the corporate stakeholder, on 17th of April 2020. This event was filed by Nanoviricides Inc with SEC on 2009-07-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On NanoViricides Inc

Net Loss for the year was (13.78 M) with profit before overhead, payroll, taxes, and interest of 0.

NanoViricides Inc Net Income Per Employee is decreasing over the last 8 years. The previous year's value of NanoViricides Inc Net Income Per Employee was -1,826,529. Further, NanoViricides Inc Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years.

NanoViricides Inc has 99 percent chance to finish above $4.75 in September

The coefficient of variation is down to -752.99 as of today. As of the 22nd of August, NanoViricides Inc secures the risk adjusted performance of (0.19), and Mean Deviation of 4.22. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NanoViricides NEW, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for NanoViricides Inc, which can be compared to its peers in the industry. Please verify NanoViricides NEW treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if NanoViricides Inc NEW is priced some-what accurately, providing market reflects its recent price of 4.85 per share. Given that NanoViricides NEW has jensen alpha of (0.60), we recommend you to check NanoViricides Inc's last-minute market performance to make sure the company can sustain itself at a future point.

Our Final Perspective on NanoViricides Inc

Whereas some firms in the biotechnology industry are either recovering or due for a correction, NanoViricides Inc may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 22nd of August 2020, we believe that at this point, NanoViricides Inc is relatively risky with very small chance of financial distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. However, our concluding 30 days recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of NanoViricides Inc NEW. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com